Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer
INTERNATIONAL UROLOGY AND NEPHROLOGY, cilt.52, sa.12, ss.2311-2320, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 52 Sayı: 12
- Basım Tarihi: 2020
- Doi Numarası: 10.1007/s11255-020-02563-2
- Dergi Adı: INTERNATIONAL UROLOGY AND NEPHROLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
- Sayfa Sayıları: ss.2311-2320
- Anahtar Kelimeler: Chronic kidney disease, End-stage renal disease, Metabolic acidosis, Alkaline treatment, Bicarbonate, LEFT-VENTRICULAR HYPERTROPHY, GLOMERULAR-FILTRATION-RATE, JOINT CONSENSUS STATEMENT, GROWTH-FACTOR 23, INSULIN-RESISTANCE, VITAMIN-D, SODIUM-BICARBONATE, PHOSPHATE BINDERS, ENDOTHELIAL DYSFUNCTION, PARATHYROID-HORMONE
- Süleyman Demirel Üniversitesi Adresli: Evet
Özet
Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.